Eisai Makes Oncology Debut With Halaven, But Development Question Marks Remain
This article was originally published in The Pink Sheet Daily
Executive Summary
Already in the small minority of drugs to gain approval via overall survival, Eisai's ability to gain additional indications for Halaven may hinge on improving the drug's progression-free survival data.